FRIENDSWOOD, Texas, May 30, 2024--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024.
FRIENDSWOOD, Texas, May 29, 2024--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-making.
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.